Age-related macular degeneration (AMD) causes significant vision loss in seniors who have it. And there are many of them. This degenerative eye disease affects more than 500,000 Quebecers, about five ...
Fact checked by Nick Blackmer Dark spots or squiggles drifting across your field of vision are called floaters.Floaters are more common as you age, when a substance called vitreous gel begins ...
The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular ...
(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...
Retinal Surgery Device Market · GlobeNewswire Inc. Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "Retinal Surgery Device ...
Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...
Intraocular inflammation following high dose aflibercept may be more common in practice than phase 3 trials found.
Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.
Cedars-Sinai investigators working to optimize a cell-based treatment for retinitis pigmentosa have uncovered how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results